Biden’s march-in policy likely to affect very few drugs

In a video released Thursday, President Joe Biden touted a new policy on march-in rights as evidence that the White House is “taking on price gouging so you won’t have to pay more for medicine that you need.” Biden and other administration officials are exaggerating the new policy’s impact on drug prices while ignoring the chilling effect it is likely to have on the commercialization of government-funded biomedical innovations.

The Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights released Thursday is an attempt to settle a decades-long disagreement over whether the Bayh-Dole Act gives NIH authority to exercise march-in rights, or issue compulsory licenses, to reduce drug costs. ...